by Barry101 | Mar 7, 2022 | Press Release, Uncategorized
OCALA, Fla., March 07, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Mar 3, 2022 | Press Release, Uncategorized
Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companiesOCALA, Fla., March 03, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM)...
by Barry101 | Jan 26, 2022 | Press Release, Uncategorized
AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm – 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long...
by Barry101 | Jan 24, 2022 | Press Release, Uncategorized
Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical...
by Barry101 | Jan 19, 2022 | Press Release, Uncategorized
Live video webcast presentation on Wednesday, January 26th at 10:00 AM ETOCALA, Fla., Jan. 19, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...
